Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Corvus Pharma Com (CRVS)

Corvus Pharma Com (CRVS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 107,268
  • Shares Outstanding, K 38,310
  • Annual Sales, $ 0 K
  • Annual Income, $ -6,000 K
  • 60-Month Beta 1.66
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.15
Trade CRVS with:

Options Overview

Details
  • Implied Volatility 111.65%
  • Historical Volatility 37.54%
  • IV Percentile 6%
  • IV Rank 33.82%
  • IV High 277.48% on 07/07/20
  • IV Low 26.91% on 07/02/20
  • Put/Call Vol Ratio 1.56
  • Today's Volume 46
  • Volume Avg (30-Day) 60
  • Put/Call OI Ratio 0.47
  • Today's Open Interest 3,615
  • Open Int (30-Day) 3,637

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.35
  • Number of Estimates 2
  • High Estimate -0.34
  • Low Estimate -0.36
  • Prior Year -0.36
  • Growth Rate Est. (year over year) +2.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.41 +16.18%
on 05/18/21
2.90 -3.45%
on 06/10/21
+0.28 (+11.11%)
since 05/11/21
3-Month
2.41 +16.18%
on 05/18/21
3.48 -19.54%
on 03/16/21
-0.44 (-13.58%)
since 03/11/21
52-Week
2.41 +16.18%
on 05/18/21
6.88 -59.30%
on 07/07/20
-0.06 (-2.10%)
since 06/11/20

Most Recent Stories

More News
Corvus Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present at the Jefferies Virtual Healthcare Conference. The presentation will be on...

CRVS : 2.80 (-1.41%)
Corvus Pharmaceuticals Completes Sale of $10 Million Through Its ATM Program

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that it has completed the sale of approximately $10 million of its common shares pursuant to the...

CRVS : 2.80 (-1.41%)
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2021 Financial Results

Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the first quarter ended March 31, 2021.

CRVS : 2.80 (-1.41%)
Corvus: Q1 Earnings Snapshot

BURLINGAME, Calif. (AP) _ Corvus Pharmaceuticals Inc. (CRVS) on Thursday reported a loss of $11.6 million in its first quarter.

CRVS : 2.80 (-1.41%)
Corvus: Q4 Earnings Snapshot

BURLINGAME, Calif. (AP) _ Corvus Pharmaceuticals Inc. (CRVS) on Thursday reported fourth-quarter net income of $27.3 million, after reporting a loss in the same period a year earlier.

CRVS : 2.80 (-1.41%)
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results

Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended December 31,...

CRVS : 2.80 (-1.41%)
Corvus Pharmaceuticals Announces Participation in Upcoming Investor Conferences

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company's management will participate in two upcoming investor conferences in March:

CRVS : 2.80 (-1.41%)
Thinking about buying stock in Avinger, Rigel Pharmaceuticals, Vistagen Therapeutics, Bio-Path, or Corvus Pharmaceuticals?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AVGR, RIGL, VTGN, BPTH, and CRVS.

AVGR : 1.1500 (+2.68%)
CRVS : 2.80 (-1.41%)
RIGL : 4.02 (-3.83%)
BPTH : 6.85 (+2.70%)
VTGN : 2.80 (-1.41%)
Corvus Pharmaceuticals Announces Closing of Public Offering of Common Stock

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced the completion of its previously announced underwritten public offering of 9,783,660 shares of its...

CRVS : 2.80 (-1.41%)
Corvus Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 8,571,429 shares of its common stock at a price...

CRVS : 2.80 (-1.41%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Corvus Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of immuno-oncology therapies to harness the immune system to attack cancer cells. Its products include CPI-444, Adenosine production inhibitor, Adenosine A2B antagonist and Interleukin-2 (IL-2)-inducible...

See More

Key Turning Points

3rd Resistance Point 2.96
2nd Resistance Point 2.91
1st Resistance Point 2.86
Last Price 2.80
1st Support Level 2.76
2nd Support Level 2.71
3rd Support Level 2.66

See More

52-Week High 6.88
Fibonacci 61.8% 5.17
Fibonacci 50% 4.64
Fibonacci 38.2% 4.12
Last Price 2.80
52-Week Low 2.41

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar